Abstract
Reliable and sensitive measures are needed to evaluate the quality of life (QoL) in patients with systemic lupus erythematosus (SLE). No lupus specific questionnaires are available. This study describes the development and validation of a disease-specific questionnaire for lupus patients, which assesses the presence and burden of 38 disease- and treatment-related symptoms: the SLE Symptom Checklist (SSC). Reliability and reproducibility were tested in respectively 87 and 28 stable SLE patients. The internal consistency (Cronbach's α coefficients 0.89) and test–retest reliability (Pearson product–moment correlation coefficient between 0.67 and 0.87) were satisfactory. Concurrent validity was supported by significant, but moderate correlations with other measures of subjective well-being and functional status. Responsiveness was measured in 17 patients with lupus nephritis treated with cyclophosphamide, at start of therapy and 1 year thereafter. A significant change in number of symptoms and total distress level was found. It is concluded that the SSC has satisfactory psychometric properties and appears suitable for both clinical and research purposes.
Similar content being viewed by others
References
Liang MH, Rogers M, Larson M, et al. The psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1984; 27: 13–19.
Joyce K, Berkebile C, Hastings C, Yarboro C. Health status and disease activity in systemic lupus erythematosus. Arthritis Care Res 1989; 2: 65–69.
Wekking EM, Vingerhoets AJ, van Dam AP, Nossent JC, Swaak AJ. Daily stressors and systemic lupus erythematosus: A longitudinal analysis-first findings. Psychother Psychosom 1991; 55: 108–113.
Wekking EM, Nossent JC, van Dam AP, Swaak AJ. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom 1991; 55: 126–131.
Dobkin PL, Fortin PR, Joseph L, et al. Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus. Arthritis Care Res 1998; 11: 23–31.
Sutcliffe N, Clarke AE, Levinton C, et al. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol 1999; 26: 2352–2356.
Archenholtz B, Burckhardt CS, Segesten K. Quality of life of women with systemic lupus erythematosus or rheumatoid arthritis: Domains of importance and dissatisfaction. Qual Life Res 1999; 8: 411–416.
Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 447–454.
Boumpas DT, Fessler BJ, Austin HA III, et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123: 42–53.
Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156: 1337–1344.
Klippel JH. Systemic lupus erythematosus. Treatment-related complications superimposed on chronic disease (clinical conference). JAMA 1990; 263: 1812–1815.
Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1996; 8: 430–437.
Burckhardt CS, Archenholtz B, Bjelle A. Measuring the quality of life of women with rheumatoid arthritis or systemic lupus erythematosus: A Swedish version of the Quality of Life Scale (QOLS). Scand J Rheumatol 1992; 21: 190–195.
Burckhardt CS, Archenholtz B, Bjelle A. Quality of life of women with systemic lupus erythematosus: A comparison with women with rheumatoid arthritis. J Rheumatol 1993; 20: 977–981.
Abu Shakra M, Mader R, Langevitz P, et al. Quality of life in systemic lupus erythematosus: A controlled study. J Rheumatol 1999; 26: 306–309.
Hanly JG. Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: Results of a cross-sectional study. Lupus 1997; 6: 243–247.
Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 309–313.
Rood MJ, Borggreve SE, Huizinga TWJ. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol 2000; 27: 2057–2059.
Thumboo J, Fong KY, Ng TP, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26: 97–102.
Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 1608–1614.
Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol 1997; 24: 2145–2148.
Hochberg MC, Sutton JD. Physical disability and psychosocial dysfunction in systemic lupus erythematosus. J Rheumatol 1988; 15: 959–964.
Milligan SE, Hom DL, Ballou SP, et al. An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. J Rheumatol 1993; 20: 972–976.
Krupp LB, LaRocca NG, Muir NJ, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121–1123.
Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis 1999; 58: 379–381.
Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 1996; 5: 190–195.
Laupacis A, Pus N, Muirhead N, et al. Disease-specific questionnaire for patients with a renal transplant. Nephron 1993; 64: 226–231.
Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–840.
Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabetic Med 1994; 11: 253–261.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.
Huiskes CJAE, Kraaimaat FW, Bijlsma JWJ. De ontwikkeling van de IRGL. Een instrument om gezondheid te meten bij pati Ënten met reuma/Development of a Dutch health status measure for patients with arthritis. Gedrag en Gezondheid 1990; 18: 78–89.
Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum 1980; 23: 146–152.
Wald FD, Mellenbergh GJ. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS)/The shortenedversion of the Dutch translation of the Profile of Mood States (POMS). Nederlands Tijdschrift voor de Psychologie en haar Grensgebieden 1990; 45: 86–90.
Groot de MH. Psychometrische aspecten van een stemmingsschaal (Verkorte POMS) /Psychometric characteristics of a moodstates inventory: ShortenedPOMS. Gedrag en Gezondheid 1992; 20: 46–51.
Reddon JR, Marceau R, Holden RR. A confirmatory evaluation of the Profile of Mood States: convergent and discriminant item validity. J Psychopathol Behavioral Assess 1985; 7: 243–259.
Aaronson NK, Acquadro C, Alonso J, et al. International Quality of Life Assessment (IQOLA) Project. Qual Life Res 1992; 1: 349–351.
Ware JE. SF-36 Health Survey. Manual and Interpretation Guide. Boston, Massachusetts: The Health Institute, New England Medical Center, 1993.
Zee van der K, Sanderman R, Heyink J. De psychometrische kwaliteiten van de MOS 36-item Short Form Health Survey (SF-36) in een Nederlandse populatie/The psychometric qualities of the MOS 36-item Short Form Health Survey (SF-36) in a Dutch population. T Soc Gezondheidsz 1993; 71: 183–191.
Pouchot J, De Bandt M, Guillevin L, et al. Psychometric properties of the SF-36 and the AIMS2-SF in patients with systemic lupus erythematosus (SLE). Qual Life Res 1999; 8: A153.
Gladman D, Urowitz M, Fortin P, et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol 1996; 23: 1953–1955.
StrandV, Gladman D, Isenberg D, et al. Outcome measures to be usedin clinical trials in systemic lupus erythematosus. J Rheumatol 1999; 26: 490–497.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334.
Snoek FJ. Quality of life: a closer look at measuring patients' well-being. Diabetes Spectrum 2000; 13: 24–28.
Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990; 17: 1450–1452.
Wysenbeek AJ, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. Br J Rheumatol 1993; 32: 633–635.
Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol 1998; 25: 892–895.
Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 101–107.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grootscholten, C., Ligtenberg, G., Derksen, R. et al. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res 12, 635–644 (2003). https://doi.org/10.1023/A:1025176407776
Issue Date:
DOI: https://doi.org/10.1023/A:1025176407776